Solid oral dosage form containing an enhancer

Details Solid oral dosage form containing an enhancer Solid oral dosage form containing an enhancer

2000-02-22

2010-02-09

Lundgren, Jeffrey S. (Department: 1639)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Biocides; animal or insect repellents or attractants

C424S464000, C424S469000

Reexamination Certificate

active

07658938

ABSTRACT:
The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

REFERENCES:
patent: 4525339 (1985-06-01), Behl et al.
patent: 4656161 (1987-04-01), Herr
patent: 4789547 (1988-12-01), Song et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5190748 (1993-03-01), Bachynsky et al.
patent: 5221734 (1993-06-01), Burk et al.
patent: 5229130 (1993-07-01), Sharma et al.
patent: 5288497 (1994-02-01), Stanley et al.
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5541155 (1996-07-01), Leone-Bay et al.
patent: 5631347 (1997-05-01), Baker et al.
patent: 5650386 (1997-07-01), Leone-Bay et al.
patent: 5714477 (1998-02-01), Einarsson
patent: 5736161 (1998-04-01), Garces et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5854281 (1998-12-01), Uekama et al.
patent: 5863555 (1999-01-01), Heiber et al.
patent: 5912009 (1999-06-01), Venkateshwaran et al.
patent: 5952000 (1999-09-01), Venkateshwaran et al.
patent: 5977175 (1999-11-01), Lin
patent: 6001390 (1999-12-01), Yum et al.
patent: 6017559 (2000-01-01), Mulqueen et al.
patent: 6124261 (2000-09-01), Stevenson et al.
patent: 6200602 (2001-03-01), Watts et al.
patent: 6270804 (2001-08-01), Getz et al.
patent: 6326360 (2001-12-01), Kanazawa et al.
patent: 6372728 (2002-04-01), Ungell
patent: 6379960 (2002-04-01), Popoff et al.
patent: 6468559 (2002-10-01), Chen et al.
patent: 6638530 (2003-10-01), Ishibashi et al.
patent: 6747014 (2004-06-01), Teng et al.
patent: 7154002 (2006-12-01), Bressi et al.
patent: 2003/0176397 (2003-09-01), Lichtenberger
patent: 2004/0087631 (2004-05-01), Bacopoulos et al.
patent: 2006/0210639 (2006-09-01), Liversidge et al.
patent: 2007/0060509 (2007-03-01), Kanikanti et al.
patent: 2007/0148228 (2007-06-01), Cumming et al.
patent: 2007/0196464 (2007-08-01), Cumming et al.
patent: 2007/0238707 (2007-10-01), Leonard
patent: 2007/0292512 (2007-12-01), Leonard et al.
patent: 2008/0275001 (2008-11-01), Cumming et al.
patent: 0370481 (1989-11-01), None
patent: 0376534 (1990-07-01), None
patent: 0497162 (1992-08-01), None
patent: 0517211 (1992-12-01), None
patent: 0580074 (1994-01-01), None
patent: 953626 (1964-03-01), None
patent: (11) 63119 (1989-11-01), None
patent: (11)63119 (1995-03-01), None
patent: 59 073600 (1984-04-01), None
patent: 03 275633 (1991-12-01), None
patent: 2068689 (1996-11-01), None
patent: WO 8404674 (1984-12-01), None
patent: WO 93/05903 (1993-04-01), None
patent: WO 93/21907 (1993-11-01), None
patent: WO 9522319 (1995-08-01), None
patent: WO 9534294 (1995-12-01), None
patent: WO 97/05903 (1997-02-01), None
patent: WO 99/01579 (1999-01-01), None
patent: WO 99/02120 (1999-01-01), None
patent: WO 99/02485 (1999-01-01), None
patent: WO 99/45934 (1999-09-01), None
patent: WO 00/22909 (2000-04-01), None
patent: WO 00/50012 (2000-08-01), None
patent: WO 02/092070 (2002-11-01), None
patent: WO 03/047493 (2003-06-01), None
patent: WO 2005/055973 (2005-06-01), None
Oda et al., Proc. Int'l Symp. Control. Rel. Bioact. Mater. 24 (1997) pp. 283-284.
Appendix A: Webpage publication provided by Lambent Technologies—www.petroferm.com/prodinfo.asp?bus=2&mkt=4&app=3.
Lambent Technologies: Technical Data Sheet for Lumulse L-4, Lumulse L-12 and Lumulse L-23.
“McGraw-Hill Dictionary of Chemical Terms”; McGraw-Hill Book Company: Ed. S.P. Parker, New York 1985 (pp. 208, 209 and 251).
Andriuoli et al.,. Haemostasis 20(suppl 1):154-158 (1990).
Lindmark et al., J. Pharm. Ex. Therapeutics275(2):958-964 (1995).
Aungst, B.J. et al., Enhancement of the Intestinal Absorption of Peptides and Non-peptides,J. of Controlled Release(1996), 41:19-31.
Lindmark, T. et al., Mechanism of Absorption Enhancement in Humans After Rectal Administration of Ampicillin in Suppositories Containing Sodium Caprate,Pharmaceutical Research(1997), 14: 930-935.
Anderberg, E.K. et al., Sodium Caprate Elicits Dilatations in Human Intestinal Tight Junctions and Enhances Drug Absorption by the Paracellular Route,Pharmaceutical Research(1993), 10: 857-864.
Yeh, P. et al., Effect of Medium-chain Glycerides on Physiological Properties of Rabbit Intestinal Epithelium in Vitro,Pharmaceutical Resarch-(1994), 11:1148-1154.
Artursson, P., Epithelial Transport of Drugs in Cell Culture. I: A Model for Studying the Passive Diffusion of Drugs over Intestinal Absorbative (Caco-2) Cells,J. Pharmaceutical Studies(1990), 79: 476-482.
Doluisio, J.T. et al., Drug Absorption I: An In Situ Rat Gut Technique Yielding Realistic Absorption Rates,J. Pharmaceutical Studies(1969), 59: 1196-1200.
Brayden, D. et al., Heparin Absorption Across the Intestine: Effects of Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate In Rat In Situ Intestinal Instillations and in Caco-2 Monolayers,Pharmaceutical Research(1997), 14:1772-1779.
Cumming, K.I. and A.J. Winfield, In Vitro Evaluation of a Series of Sodium Carboxylates as Dermal Penetration Enhancers,Int. J. Pharm.(1994), 108: 141-148.
Tomita, M. et al., Enhancement of Colonic Drug Absorption by the Paracellular Permeation Route,Pharmaceutical Research(1988), 5: 341-346.
Aungst, Bruce K. et al., Enhancement of the Intestinal Absorption of Peptides and Non-Peptides, Journal of Controlled Release 41 (1996) pp. 19-31.
Palin, K. J. et al., The Oral Absorption of Cefoxitin from Oil and Emulsion Vehicles in Rats, International Journal of Pharmaceutics, 33 (1986) pp. 99-104.
Tomita, M. et al., Enhancement of Colonic Drug Absorption by the Paracellular Permeation Route, Pharmaceutical Research vol. 5, No. 6, (1988), pp. 341-346.
Murakami, M. et al., Effect of Oleic Acid Vesicles on Intestinal Absorption of Carboxyfluorescein in Rats, Pharmaceutical Research, vol. 3, No. 1, 1986, pp. 35-40.
Muranushi, N. et al., The Effects Of Fatty Acids and Their Derivatives on The Intestinal Absorption of Insulin In Rats, Drug Development and Industrial Pharmacy, 19(8), pp. 929-941 (1993).
Tomita, M. et al., Differences in the Enhancing Effects of Sodium Caprate on Colonic and Jejunal Drug Absorption, Pharmaceutical Research, vol. 9, No. 5, 1992, pp. 648-653.
Tomita, M. et al., Enhancement of Colonic Drug Absorption by the Transcellular Permeation Route, Pharmaceutical Research vol. 5., No. 12 (1988), pp. 786-789.
Anderberg, E. K. et al., Sodium Caprate Elicits Dilatations in Human Intestinal Tight Junctions and Enhances Drug Absorption by the Paracellular Route, Pharmaceutical Research vol. 10, No. 6, 1993, pp. 857-864.
Tomita, Mikio, et al., Absorption-Enhancing Mechanism of Sodium Caprate and Decanoylcarnitine in Caco-2 Cells , The Journal of Pharmacology and Experimental Therapeutics, vol. 272, No. 2, 1995, pp. 739-743.
Sawada, T., et al., Role of Paracellular Pathway in Nonelectrolyte Permeation Across Rat Colon Epithelium Enhanced by Sodium Caprate and Sodium Caprylate, Pharmaceutical Research, vol. 8, No. 11, 1991, pp. 1365-1371.
Aungst, “Structure/effect studies of fatty acid isomers as skin penetration enhancers and skin irritants,” Pharm. Res. 6:244-247 (1989).
Chan et al., “Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS,” Invest. New Drugs 15:195-206 (1997).
Mishima et al., “Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats,” J. Pharmacobio-Dyn., 10:624-631 (1987).
Morishita et al., “Site-Dependent Effect of Aprotinin, Sodium Caprate, Na2EDTA and Sodium Glycocholate on Intestinal Absorption of Insulin,” Biol. Pharm. Bull. 16:68-72 (1993).
Schneider et al., “Evaluation of drug penetration into human skin ex viv

Affiliated with

Also associated with

Rating

Solid oral dosage form containing an enhancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Solid oral dosage form containing an enhancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid oral dosage form containing an enhancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4233092